Cargando…

Soluble Klotho: a possible predictor of quality of life in acromegaly patients

PURPOSE: Although quality of life (QoL) is improved in patients with acromegaly after disease control, QoL correlates only weakly with traditional biomarkers. Our objective is to investigate a potential relation between the new serum biomarker soluble Klotho (sKlotho), GH and insulin-like growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coopmans, Eva C., El-Sayed, Nour, Frystyk, Jan, Magnusson, Nils E., Jørgensen, Jens O. L., van der Lely, Aart-Jan, Janssen, Joop A. M. J. L., Muhammad, Ammar, Neggers, Sebastian J. C. M. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343750/ https://www.ncbi.nlm.nih.gov/pubmed/32333268 http://dx.doi.org/10.1007/s12020-020-02306-4

Ejemplares similares

Approach to the Patient With Treatment-resistant Acromegaly
por: Coopmans, Eva C, et al.
Publicado: (2022)

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life
por: Varewijck, A J, et al.
Publicado: (2014)

The position of combined medical treatment in acromegaly
por: Coopmans, Eva C., et al.
Publicado: (2019)

Pregnancy and acromegaly
por: Muhammad, Ammar, et al.
Publicado: (2016)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Soluble Klotho protein as a novel serum biomarker in patients with acromegaly
por: Dąbrowska, Anna M., et al.
Publicado: (2014)

Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity
por: Schweizer, Júnia R O L, et al.
Publicado: (2021)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
por: Vila, Greisa, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Towards an Earlier Diagnosis of Acromegaly and Gigantism
por: Sisco, Jill, et al.
Publicado: (2021)

Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study
por: Coopmans, Eva C, et al.
Publicado: (2021)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

ACRODAT® and AcroVoice: an insight into a holistic approach to the management of acromegaly
por: Lundie, Mark, et al.
Publicado: (2019)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

MON-327 Soluble Alpha Klotho and IGF-I Before Surgery as Prognostic Factors to Acromegaly Long-term Remission
por: de Oliveira Longo Schweizer, Junia Ribeiro, et al.
Publicado: (2020)

OR32-2 Alpha Klotho as a Marker of Disease Activity in Acromegaly
por: Schweizer, Junia, et al.
Publicado: (2019)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

New Insights into the Mechanism of Action of Soluble Klotho
por: Dalton, George D., et al.
Publicado: (2017)

ODP353 Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly
por: Culler, Michael, et al.
Publicado: (2022)

Development of ACRODAT(®), a new software medical device to assess disease activity in patients with acromegaly
por: van der Lely, Aart J., et al.
Publicado: (2017)

Association of pre- and postoperative αKlotho levels with long-term remission after pituitary surgery for acromegaly
por: Neidert, Marian Christoph, et al.
Publicado: (2022)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

Soluble klotho may be a marker of phosphate reabsorption
por: Tan, Sven-Jean, et al.
Publicado: (2017)

Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis
por: Memmos, Evangelos, et al.
Publicado: (2019)

Soluble klotho as an effective biomarker to characterize inflammatory states
por: Wu, Shou-En, et al.
Publicado: (2022)

Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies
por: Coopmans, Eva C., et al.
Publicado: (2019)

OR24-02 Identification of Membrane Proteins That Enhance the Responsiveness of the Ghrelin Receptor
por: Prins, Karina, et al.
Publicado: (2020)

Aging and sex affect soluble alpha klotho levels in bonobos and chimpanzees
por: Behringer, V., et al.
Publicado: (2018)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
por: Petrossians, Patrick, et al.
Publicado: (2017)

Soluble α-Klotho Serum Levels in Chronic Kidney Disease
por: Rotondi, Silverio, et al.
Publicado: (2015)

Performance of soluble Klotho assays in clinical samples of kidney disease
por: Neyra, Javier A, et al.
Publicado: (2019)

Insulin Resistance in Patients With Acromegaly
por: Vila, Greisa, et al.
Publicado: (2019)

Overweight and obesity in type 1 diabetes is not associated with higher ghrelin concentrations
por: Özcan, Behiye, et al.
Publicado: (2021)

Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states
por: Özcan, Behiye, et al.
Publicado: (2017)

Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels
por: Poelzl, G., et al.
Publicado: (2018)

Klotho: A Possible Role in the Pathophysiology of Nephrotic Syndrome
por: Tomo, Sojit, et al.
Publicado: (2022)

Association of Soluble Klotho Level with Adverse Outcomes in Patients on Maintenance Hemodialysis
por: Yu, Li-xia, et al.
Publicado: (2020)

Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment
por: Martín-Vírgala, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2pu2genej13cj70hvokrgbh2v7